Clinical Trials: Providing New Hope and Opportunity in The Face of Retinal Conditions
Research at Austin Retina
Austin Retina is nationally recognized for its participation in ground-breaking, pivotal clinical trials for over thirty years, which has allowed us to offer our patients the opportunity to receive novel procedures and therapies through enrollment in clinical research studies. We pride ourselves on being at the forefront of clinical research and will always recognize the impact on those who benefit the most: our patients.
For referring doctors or patients who wish to learn more about our research protocols or activities, please continue reading below or contact our office at (512) 451-0103.
Clinical trials are scientific medical research into the appropriateness, effectiveness and safety of new treatments in humans. The goal of clinical trials—whether for vision-related care or any other medical discipline—is to advance medical knowledge and help improve patient care. Specifically, clinical trials determine whether a new medication, device or treatment strategy…
- Improves patient outcomes
- Offers real benefit
- Causes no harm
Designed for safety, accuracy and advancement of quality care.
Clinical trials are designed to produce the highest-quality data possible… while ensuring the safety of the patients in each study. Trials are conducted in adherence to strict standards, and they are governed and reviewed by institutional review boards (IRBs), which exist to protect patients’ health and safety.
Clinical trials are one of the last steps in the careful, detailed process of studying a new treatment. (Investigation begins in the laboratory, and promising methods may proceed to non-human testing and then human trials.) At the same time, patients enrolled in a new treatment’s clinical trial may be the first to benefit from that treatment. Every treatment in use today was investigated and approved for use through the clinical trials process, and all future medical treatments will have gone through this process.
Why consider enrolling in a retina-related clinical trial?
Retinal care, like the field of medicine itself, is always advancing and changing. New methods and medications are constantly being developed to slow disease process, improve vision outcomes, and improve quality of life. At Austin Retina, we participate in clinical trials to offer new options, opportunities and hope for people who need them to protect, preserve or improve their eyesight. For individuals with few options or who aren’t seeing positive results, enrolling in a clinical trial provides access to the promising new vision therapies of tomorrow.
Clinical trials open for enrollment at Austin Retina.
Our specialists are proud to take part in clinical research trials for many common retinal conditions. Below are trials for which we are currently enrolling new patients. If you’d like more information on any of the trials below, please fill out our contact form and indicate which trial you’re interested in.
Clinical Trials Ongoing
Status: Open for Enrollment
Bayer AG 20968 “Pulsar”
ClinicalTrials.gov Identifier: NCT04423718
High-dose aflibercept vs aflibercept
ClinicalTrials.gov Identifier: NCT04005352
Intravitreal brolucizumab vs intravitreal aflibercept
ClinicalTrials.gov Identifier: NCT04747197
EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with wet AMD
Ionis Pharmaceuticals “GOLDEN 696844-CS5”
ClinicalTrials.gov Identifier: NCT03815825
Subcutaneous IONIS-FB-LRx vs sham
ClinicalTrials.gov Identifier: NCT03972709
Intravitreal RO7171009 vs sham
Iveric Bio “ISEE2008”
ClinicalTrials.gov Identifier: (not on clinicaltrials.gov)
Zimura vs sham
ClinicalTrials.gov Identifier: NCT04503551
Port Delivery System of ranibizumab
ClinicalTrials.gov Identifier: NCT04108156
Port Delivery System of ranibizumab vs intravitreal ranibizumab
ClinicalTrials.gov Identifier: NCT04429503
High-dose aflibercept vs aflibercept
ClinicalTrials.gov Identifier: NCT04418427
ADVM-022 Intavitral gene therapy for DME
KSI-301 vs aflibercept in the treatment of DME (recruiting in RR as well)
Novartis RTH258D2301 "CONDOR"
Brolucizumab compared to PRP in subjects with PDR
Santen Pharmaceutical Co. “Lumina”
ClinicalTrials.gov Identifier: NCT03711929
Intravitreal DE-109 vs sham
ClinicalTrials.gov Identifier: NCT04592419
KSI-301 vs aflibercept in the treatment of RVO (recruiting in RR as well)
Diopsys, Inc. “Indigo”
Evaluation of retinal function in eyes with diabetic retinopathy treated with anti-VEGF using Flicker ERG
Verily Life Sciences, LLC “ARDA-003”
Evaluation of investigational retinal imaging camera study
Status: Closed for Enrollment
F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”
Faricimab vs. Aflibercept in Patients With wAMD.
F. Hoffmann La Roche/Genentech (Protocol GR40398) “Rhine” Faricimab vs. Aflibercept in Patients With Diabetic Macular Edema
Novartis Pharmaceuticals (Protocol CRTH258B2301) “Kestrel”
Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novo Nordisk (Protocol NN9535-4352) “Focus” – In collaboration with Texas Diabetes & Endocrinology
Semaglutide vs. placebo in Type II diabetics.
F. Hoffmann La Roche/Genentech (Protocol GR40548) “Archway”
Port Delivery System (PDS) vs. Ranibzumab in Patients With wAMD.
Ophthotech (Protocol OPH2005)
Anti-C5 aptamer in patients with Stargardt Disease.
Samsung Bioepis (Protocol SB11-G31-AMD)
Intravitreal SB11 (Proposed Ranibizumab biosimilar) compared to Ranibizumab alone in patients with wAMD.
Ophthotech (Protocol OPH2003)
Anti-C5 aptamer in patients with Geographic Atrophy.
DRCR/JAEB (Protocol W)
AntiVEGF in prevention of vision threatening Diabetic Retinopathy in high risk eyes.
Novartis (Protocol RFB002/Ranibizumab) “RAINBOW”
Ranibizumab vs laser in infants with ROP.
DRCR/JAEB (Protocol TX)
5 Year follow-up exam of subjects who completed DRCR protocol “T”, a comparison of Aflibercept, Bevacizumab and Ranibizumab in patients with DME.
DRCR/JAEB (Protocol AA)
Ultrawide-Field imaging vs traditional 7F fundus photography in patients with diabetic retinopathy in monitoring disease progression.
Clinical Trials Completed:
Opthea (Protocol OPT-302-1002)
Intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in patients with wAMD.
Allergan (Protocol 1771-201-008) “Maple”
Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration.
Allergan (Protocol 150998-006) “SEQUOIA”
Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Alcon (Protocol RTH258-C001) “HAWK”
RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
F. Hoffmann La Roche/Genentech (Protocol GX29176) “CHROMA” Phase III
Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD.
Allergan (Protocol 190342-038) “BEACON”
Brimonidine DDS vs Sham in patients with Geographic Atrophy due to Dry AMD.
Regeneron (Protocol R910-3-AMD-1517) “ONYX”
Co-formulation anti-Ang2+Aflibercept for patients with treatment-naïve CNV.
F. Hoffmann La Roche/Genentech (Protocol BP29647) “AVENUE”
RO6867461 vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Regeneron (Protocol R2176-3-AMD-1417) “CAPELLA”
REGN2176-3 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
Ophthotech (Protocol OPH1002) “ECLIPSE” Phase III
Intravitreal injections of FOVISTA in combination with Lucentis versus Lucentis as monotherapy in patients with treatment-naïve Wet AMD.
LPath (Protocol LT1009-Oph-003) “NEXUS” Phase 2A
Intravitreal ISONEP (Sonepcizumab LT-1009) as monotherapy or adjunctive therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea as monotherapy in patients with Wet AMD.
NeoVista (Protocol NVI-114) “CABERNET”
Prospective study of the Epi-Rad90 ophthalmic system in patients with subfoveal CNV secondary to AMD.
Regeneron (Protocol VGFT-OD-0910.03)
Safety and tolerability extension study of intravitreal VEGF Trap-Eye in patients with CVN secondary to AMD.
Regeneron (Protocol VGFT-OD-0606) “VIEW”
Safety and efficacy of intravitreal VEGF Trap versus ranibizumab in patients with CNV secondary to AMD.
Genentech (Protocol FVF3426g) “HORIZON”
Intravitreal ranibizumab extension study for patients who have completed a Genentech ranibizumab trial.
Genentech (Protocol FVF4579g) “HARBOR”
Safety and efficacy of 0.5mg and 2.0mg ranibizumab intravitreal injection administered monthly versus as-needed in patients with subfoveal CNV secondary to AMD.
GlaxoSmithKline (Protocol MD7110852)
Dose-evaluation study of pazopanib eye drops versus ranibizumab in patients with CNV secondary to AMD.
Acucela (Protocol 4429-201)
Safety and tolerability of oral ACU-4429 in patients with Dry AMD.
Allergan (Protocol 190342-032D-03)
Safety and efficacy of Brimonidine Tartrate PS DDS in patients with geographic atrophy.
Allergan (Protocol 206207-019)
PS DDS with ranibizumab in patients with CNV secondary to AMD
Allergan (Protocol 211745-001-01) “SIRIUS”
Safety and efficacy of intravitreal AGN211745 in patients with CNV secondary to AMD.
OPKO (Protocol “COBALT”)
Intravitreal bevasiranib versus Lucentis in patients with CNV secondary to AMD.
Genentech (Protocol FVF2587g) “ANCHOR”
Intravitreal ranibizumab versus Visudyne PDT in patients with CNV secondary to AMD.
Genentech (Protocol FVF2598g) “MARINA”
Intravitreal ranibizumab versus sham in occult CNV secondary to AMD.
Genentech (Protocol FVF3192g) “PIER”
Intravitreal ranibizumab in patients with minimally classic CNV secondary to AMD.
Genentech (Protocol FVF3689g) “SAILOR”
Intravitreal ranibizumab in patients with naïve or previously treated CNV secondary to AMD.
Eyetech, Inc./Pfizer (Protocol 1023) “LEVEL”
Intravitreal Macugen in patients with stable, previously treated CNV secondary to AMD.
Alcon Research , Ltd. (Protocol C-02-60)
Juxtascleral anacortave acetate versus sham CNV risk reduction study in patients with Dry AMD.
Alcon Research, Ltd. (Protocol C-01-99)
Juxtascleral anacortave acetate versus sham in patients with predominantly classic CNV secondary to AMD.
CIBA (Protocol BPD OCR-005) “VAM”
Visudyne T-IND study in patients with CNV secondary to AMD.
Miravant/Pharmacia (Protocol SNET2-98EA004)
SnET2 Photodynamic therapy versus sham in patients with CNV secondary to AMD.
Regeneron (Protocol VGFTe-OD-1411) “PANORAMA”
Aflibercept vs sham in patients with NPDR.
Aerpio Therapeutics, Inc. (Protocol AKB-9779-CI-5001) “TIME-2B”
A Novel Tie 2 Activator, AKB-9778, use once or twice daily vs sham in patients with NPDR.
Clearside Biomedical (Protocol CLS1004-201) “TYBEE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in DME.
Roche (Protocol BP30099) “BOULEVARD”
Anti-VEGF + anti-Ang2 for patients with DME.
Regeneron (Protocol R910-3-DME-1518) “RUBY”
Co-formulation anti-Ang2+Aflibercept for patients with DME.
Allegro (Protocol DME-202B) “Del Mar” Stage 1 and 2
Luminate vs Avastin in patients with DME.
Allegro (Protocol PVD-202) “Pacific”
Luminate vs BSS for PVD inducement in patients with NPDR.
Allergan (Protocol 150998-004) “PALM”
Evaluation of Abicipar Pegol (AGN-150998) versus ranibizumab in patients with vision loss due to diabetic macular edema.
Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)
Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema.
DRCR/JAEB (Protocol U)
Evaluation of combination corticosteroid plus anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes.
Regeneron (Protocol VGFT-OD-1009.01) “VISTA”
Safety and efficacy of intravitreal VEGF Trap-Eye in patients with diabetic macular edema.
iCo Therapeutics (Protocol 2010-007-03-DME) “iDEAL”
Intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in patients with foveal diabetic macular edema.
DRCR/JAEB (Protocol T)
Comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab in patients with diabetic macular edema.
DRCR/JAEB (Protocol GEN)
Genes in Diabetic Retinopathy Project.
DRCR/JAEB (Protocol V)
Prompt laser + deferred aflibercept vs. Observation + deferred aflibercept vs. Prompt aflibercept, (1:1:1), for the treatment of diabetic macular edema in treatment-naïve patients with very good vision (20/25 or better).
DRCR (Protocol S)
Prompt PRP versus intravitreal ranibizumab with deferred PRP in patients with proliferative diabetic retinopathy.
Allergan (Protocol 206207-024)
Comparing the safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.
Genentech (Protocol FVF4170g) “RISE”
Safety and efficacy of intravitreal ranibizumab versus sham injection in patients with clinically significant macular edema secondary to diabetes mellitus.
Allergan (Protocol 206207-011)
Dexamethasone PS DDS versus sham in patients with diabetic macular edema.
DRCR/JAEB (Protocol 1A)
Modified laser treatment in patients with diabetic macular edema.
DRCR/JAEB (Protocol B)
Observation of diabetic macular edema following scatter laser therapy.
DRCR/JAEB (Protocol F)
Triamcinolone with focal laser in patients with diabetic macular edema.
Allergan (Protocol 206207-018)
PS DDS in patients with diabetic macular edema status post vitrectomy.
Alimera Sciences , Inc. (Protocol C-01-05-001) “FAME”
Intravitreal Fluocinolone Acetonide versus sham in patients with diabetic macular edema.
Clearside Biomedical (Protocol CLS1003-302) “Topaz”
Supra-choroidal Triamcinolone with Intravitreal Anti-VEGF vs sham Suprachoroidal procedure with Intravitreal Anti-VEGF in RVO with ME.
Clearside Biomedical (Protocol CLS1003-301) “SAPPHIRE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME.
Allergan (Protocol 208397-001)
Safety and efficacy of a single dose of AGN-208397 in patients with macular edema due to retinal vein occlusion.
Genentech (Protocol FVF4165g) “BRAVO”
Ranibizumab versus sham in patients with branch retinal vein occlusion.
Genentech (Protocol FVF4166g) “CRUISE”
Intravitreal ranibizumab versus sham in patients with central retinal vein occlusion.
Genentech (Protocol FVF4967g ) “SHORE”
Dosing regimens of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Allergan (Protocol 206207-009)
Intravitreal dexamethasone PS DDS versus sham in patients with central or branch retinal vein occlusion.
Mallinckrodt (Protocol MNK61074105)
Acthar in patients with severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Eyegate (Protocol EGP-437-006)
Iontophorectic dexamethasone for non-infectious anterior Uveitis.
Clearside Biomedical (Protocol CLS1001-301) “Peachtree”
Supra-choroidal Triamcinolone for non-infectious Uveitis.
Santen (Protocol 32-007) “SAKURA”
Safety and efficacy of DE-109 for the treatment of active, non-infectious posterior segment uveitis.
EyeGate (Protocol EGP-437-004)
Safety and efficacy of iontophoretic dexamethasone phosphate compared to prednisolone acetate 1% in patients with non-infectious anterior segment uveitis.
Alcon Research, LTD. (Protocol C-04-18)
Evaluation of BSS irrigating solution during vitrectomy.
Inspire (Protocol 06-102)
Intravitreal Denufosol in patients with rhegmatogenous retinal detachment.
Allegro Ophthalmics, LLC (Protocol VMA-202)
Safety and efficacy of intravitreal ALG-1001 vs. BSS injection in patients with symptomatic vitreomacular adhesion.
ThromboGenics (Protocol TG-MV-006) “MIVI-TRUST”
Microplasmin intravitreal injection versus sham injection in patients with vitreomacular traction.
DigiSight (Protocol DS2001510k) “PAXOS Checkup”
Mobile device self visual acuity testing vs ETDRS.
Rohrer (Protocol 513403-T)
Pharmacokinetics and safety of lomefloxacin eye drops.
Parke-Davis (Protocol 919-220-0)
A multiple dose safety study on enoxacin eye drops.
Otsuka (Protocol 67-90-201)
Pharmacokinetics and safety of OPC-14117 eye drops.
Pharmos (Protocol P-5604:107)
Safety and efficacy of loteprednol etabonate in patients with GPC secondary to contact lens wear.